FDA Accepts Aflibercept sBLA for Treatment of Diabetic Retinopathy
Pharmacy Times
JULY 3, 2022
If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.
Let's personalize your content